search
Back to results

SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke (SEGA)

Primary Purpose

Stroke

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Sedation
General Anesthesia (GA)
Intra-arterial Thrombectomy
Sponsored by
The University of Texas Health Science Center, Houston
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke focused on measuring Acute stroke, Cerebral Stroke

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Acute ischemic stroke due to large intracranial vessel occlusion demonstrated on CT-angiography in the following anterior circulation locations that will be treated by endovascular therapy (EVT):

    1. Internal Carotid Artery (terminal "T" or "L-type"- occlusion)
    2. Middle Cerebral Artery (MCA) M1 or proximal M2
    3. Anterior Cerebral Artery (ACA) A1 or proximal A2

      • Patients who receive IV-tPA thrombolysis are eligible provided the drug was delivered within 4.5 hours of stroke onset or last seen normal and in accordance with local hospital standard of care.
  2. Ages 18-90.
  3. National Institute of Health Stroke Scale (NIHSS) score 6-30
  4. Time of from stroke symptom onset of last seen normal to start of EVT (defined as groin puncture) ≤ 16 hours.
  5. Limited infarct core, as defined below and adapted from the 2018 American Heart Association guidelines

    1. For patients presenting ≤ 6 hours from time of symptom onset or last seen normal, Alberta Stroke Program Early Computed Tomography Score (ASPECTS) ≥ 6
    2. For patients presenting > 6 hours and ≤ 16 hours from time of symptom onset or last seen normal, they must satisfy EITHER ONE of the two following criteria:

    i. Ischemic core by CT Perfusion or MRI/MR Perfusion < 70 mL, a ratio of volume of penumbral tissue to infarct core of ≥ 1.8, and and absolute volume of penumbral tissue of ≥ 15 mL OR ii. For patients with NIHSS ≥ 10, infarct core of < 31 mL by CT Perfusion or MRI; For patients with NIHSS ≥ 20, infarct core < 51 mL.

  6. Subject willing/able to return for protocol required follow up visits.
  7. No significant pre-stroke disability (modified Rankin Score must be ≤ 2).
  8. Females of childbearing potential must have a negative serum or urine pregnancy test.
  9. Patient or patient's legally authorized representative has given Informed Consent according to Good Clinical Practices (GCP) and/or local IRB policies.

Exclusion Criteria:

  1. Coma on admission (Glasgow Coma Scale <8), need for intubation upon ED arrival, or transferred patients who present previously intubated.
  2. Severe agitation or seizures on admission that preclude safe vascular access.
  3. Loss of airway protective reflexes and/or vomiting on admission.
  4. Predicted or known difficult airway.
  5. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia.
  6. Presumed septic embolus, or suspicion of bacterial endocarditis
  7. Currently participating or has participated in any investigational drug or device study within 30 days.
  8. Inability to follow-up for 90-day assessment.
  9. Known history of allergy to anesthesia drugs.
  10. Known history or family history of malignant hyperthermia

Sites / Locations

  • Indiana University College of Medicine
  • University of Iowa Hospitals and Clinics
  • Henry Ford Health System
  • Rochester Regional Health
  • Wake Forest Baptist Health
  • Geisinger Health
  • Temple University
  • Memorial Hermann Hospital System - Memorial City Medical Center
  • Baylor College of Medicine
  • University of Texas Health Science Center Houston with Memorial Hermann Hospital System - The Medical Center
  • Memorial Hermann Hospital System - The Woodlands Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Sedation

General Anesthesia

Arm Description

The protocol does not specify a particular combination of drugs that must be used for sedation. The choice of specific drugs and dosages for achieving sedation will be up to the anesthesiologist.

The protocol does not specify a particular combination of drugs that must be used for general anesthesia. The choice of specific drugs and dosages for achieving general anesthesia will be up to the anesthesiologist.

Outcomes

Primary Outcome Measures

modified Rankin Scale (mRS)
Comparison of independent clinical outcome as measured by the modified Rankin Scale (mRS) at 90 days (scores 5 and 6 combined) among patients randomized to GA versus Sedation assessed by study personnel blinded to treatment.

Secondary Outcome Measures

Dichotomized modified Rankin Scale (mRS)
Dichotomized modified Rankin Scale (mRS) at 90 days (0-2 vs 3-6) adjusted for stratification variable
Rates of recanalization
Rates of recanalization using modified TICI scores
National Institute of Health Stroke Scale (NIHSS) scale
Early clinical improvement measured by difference NIHSS scale
modified Rankin Scale (mRS)
Independent functional outcome in General Anesthesia patients treated with inhalational vs. intravenous medications.
Quality of life as assessed by the European Quality of Life-5 Dimensions (EQ-5D) instrument
Incidence of symptomatic intracerebral hemorrhage
Safety measured by incidence of symptomatic intracerebral hemorrhage
Incidence of mortality
Safety measured by incidence of mortality
Incidence of device related complications
Safety measured by incidence of device related complications

Full Information

First Posted
August 16, 2017
Last Updated
May 10, 2023
Sponsor
The University of Texas Health Science Center, Houston
Collaborators
Stryker Neurovascular
search

1. Study Identification

Unique Protocol Identification Number
NCT03263117
Brief Title
SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke
Acronym
SEGA
Official Title
SEGA - SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke - a Randomized Comparative Effectiveness Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
July 1, 2018 (Actual)
Primary Completion Date
April 22, 2023 (Actual)
Study Completion Date
April 22, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Texas Health Science Center, Houston
Collaborators
Stryker Neurovascular

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Objectives: This study aims to estimate overall treatment benefit (improvement in disability) among acute ischemic stroke patients that are randomized to General Anesthesia (GA) compared with Sedation (CS) during endovascular therapy. Assess safety (as measured by incidence of symptomatic intracranial hemorrhage); rates of Endovascular therapy (EVT) procedural complications, reperfusion; and quality of life. Hypothesis: GA during EVT for acute ischemic stroke improves functional outcomes at 90 days compared to sedation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke
Keywords
Acute stroke, Cerebral Stroke

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
260 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sedation
Arm Type
Active Comparator
Arm Description
The protocol does not specify a particular combination of drugs that must be used for sedation. The choice of specific drugs and dosages for achieving sedation will be up to the anesthesiologist.
Arm Title
General Anesthesia
Arm Type
Active Comparator
Arm Description
The protocol does not specify a particular combination of drugs that must be used for general anesthesia. The choice of specific drugs and dosages for achieving general anesthesia will be up to the anesthesiologist.
Intervention Type
Drug
Intervention Name(s)
Sedation
Intervention Description
The protocol does not specify a particular combination of drugs that must be used for sedation. The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.
Intervention Type
Drug
Intervention Name(s)
General Anesthesia (GA)
Intervention Description
The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist. The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)
Intervention Type
Procedure
Intervention Name(s)
Intra-arterial Thrombectomy
Other Intervention Name(s)
Endovascular Therapy
Intervention Description
The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.
Primary Outcome Measure Information:
Title
modified Rankin Scale (mRS)
Description
Comparison of independent clinical outcome as measured by the modified Rankin Scale (mRS) at 90 days (scores 5 and 6 combined) among patients randomized to GA versus Sedation assessed by study personnel blinded to treatment.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Dichotomized modified Rankin Scale (mRS)
Description
Dichotomized modified Rankin Scale (mRS) at 90 days (0-2 vs 3-6) adjusted for stratification variable
Time Frame
90 days
Title
Rates of recanalization
Description
Rates of recanalization using modified TICI scores
Time Frame
post procedure within 6 hours
Title
National Institute of Health Stroke Scale (NIHSS) scale
Description
Early clinical improvement measured by difference NIHSS scale
Time Frame
24-36 hours post procedure
Title
modified Rankin Scale (mRS)
Description
Independent functional outcome in General Anesthesia patients treated with inhalational vs. intravenous medications.
Time Frame
90 days
Title
Quality of life as assessed by the European Quality of Life-5 Dimensions (EQ-5D) instrument
Time Frame
90 days
Title
Incidence of symptomatic intracerebral hemorrhage
Description
Safety measured by incidence of symptomatic intracerebral hemorrhage
Time Frame
18-36 hours post procedure
Title
Incidence of mortality
Description
Safety measured by incidence of mortality
Time Frame
18-36 hours post procedure
Title
Incidence of device related complications
Description
Safety measured by incidence of device related complications
Time Frame
18-36 hours post procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Acute ischemic stroke due to large intracranial vessel occlusion demonstrated on CT-angiography in the following anterior circulation locations that will be treated by endovascular therapy (EVT): Internal Carotid Artery (terminal "T" or "L-type"- occlusion) Middle Cerebral Artery (MCA) M1 or proximal M2 Anterior Cerebral Artery (ACA) A1 or proximal A2 Patients who receive IV-tPA thrombolysis are eligible provided the drug was delivered within 4.5 hours of stroke onset or last seen normal and in accordance with local hospital standard of care. Ages 18-90. National Institute of Health Stroke Scale (NIHSS) score 6-30 Time of from stroke symptom onset of last seen normal to start of EVT (defined as groin puncture) ≤ 16 hours. Limited infarct core, as defined below and adapted from the 2018 American Heart Association guidelines For patients presenting ≤ 6 hours from time of symptom onset or last seen normal, Alberta Stroke Program Early Computed Tomography Score (ASPECTS) ≥ 6 For patients presenting > 6 hours and ≤ 16 hours from time of symptom onset or last seen normal, they must satisfy EITHER ONE of the two following criteria: i. Ischemic core by CT Perfusion or MRI/MR Perfusion < 70 mL, a ratio of volume of penumbral tissue to infarct core of ≥ 1.8, and and absolute volume of penumbral tissue of ≥ 15 mL OR ii. For patients with NIHSS ≥ 10, infarct core of < 31 mL by CT Perfusion or MRI; For patients with NIHSS ≥ 20, infarct core < 51 mL. Subject willing/able to return for protocol required follow up visits. No significant pre-stroke disability (modified Rankin Score must be ≤ 2). Females of childbearing potential must have a negative serum or urine pregnancy test. Patient or patient's legally authorized representative has given Informed Consent according to Good Clinical Practices (GCP) and/or local IRB policies. Exclusion Criteria: Coma on admission (Glasgow Coma Scale <8), need for intubation upon ED arrival, or transferred patients who present previously intubated. Severe agitation or seizures on admission that preclude safe vascular access. Loss of airway protective reflexes and/or vomiting on admission. Predicted or known difficult airway. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia. Presumed septic embolus, or suspicion of bacterial endocarditis Currently participating or has participated in any investigational drug or device study within 30 days. Inability to follow-up for 90-day assessment. Known history of allergy to anesthesia drugs. Known history or family history of malignant hyperthermia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peng Roc Chen, MD
Organizational Affiliation
The University of Texas Health Science Center, Houston
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Andrew Barreto, MD
Organizational Affiliation
The University of Texas Health Science Center, Houston
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Carlos Artime, MD
Organizational Affiliation
The University of Texas Health Science Center, Houston
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sunil Sheth, MD
Organizational Affiliation
The University of Texas Health Science Center, Houston
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sean Savitz, MD
Organizational Affiliation
The University of Texas Health Science Center, Houston
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Claudia Pedroza, PhD
Organizational Affiliation
The University of Texas Health Science Center, Houston
Official's Role
Principal Investigator
Facility Information:
Facility Name
Indiana University College of Medicine
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
University of Iowa Hospitals and Clinics
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Facility Name
Henry Ford Health System
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
48150
Country
United States
Facility Name
Rochester Regional Health
City
Rochester
State/Province
New York
ZIP/Postal Code
14617
Country
United States
Facility Name
Wake Forest Baptist Health
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
Geisinger Health
City
Danville
State/Province
Pennsylvania
ZIP/Postal Code
17822
Country
United States
Facility Name
Temple University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19122
Country
United States
Facility Name
Memorial Hermann Hospital System - Memorial City Medical Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77024
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
University of Texas Health Science Center Houston with Memorial Hermann Hospital System - The Medical Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Memorial Hermann Hospital System - The Woodlands Medical Center
City
The Woodlands
State/Province
Texas
ZIP/Postal Code
77380
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
35857365
Citation
Tosello R, Riera R, Tosello G, Clezar CN, Amorim JE, Vasconcelos V, Joao BB, Flumignan RL. Type of anaesthesia for acute ischaemic stroke endovascular treatment. Cochrane Database Syst Rev. 2022 Jul 20;7(7):CD013690. doi: 10.1002/14651858.CD013690.pub2.
Results Reference
derived

Learn more about this trial

SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke

We'll reach out to this number within 24 hrs